Brought to you by 
Spectrum to have full ownership of Zevalin after getting ex-US rights from Bayer
05 Mar 2012
Executive Summary
Bayer HealthCare Pharmaceuticals AG has licensed Spectrum Pharmaceuticals Inc. (solid and hematological cancers) the ex-US marketing and sales rights to Zevalin (the antibody ibritumomab linked to the radioisotope tiuxetan), indicated for follicular B-cell non-Hodgkin’s lymphoma. The deal includes patents and existing inventory.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spectrum to have full ownership of Zevalin after getting ex-US rights from Bayer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice